{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:55:34Z","timestamp":1791424534598,"version":"4.3.3"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1684\/bdc.2013.1857","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:43Z","timestamp":1565726323000},"page":"1283-1293","source":"Crossref","is-referenced-by-count":11,"title":["M\u00e9soth\u00e9liomes malins pleuraux : le point en 2013"],"prefix":"10.1016","volume":"100","author":[{"given":"Karine","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Reviron-Rabec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bergot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanu\u00e8le","family":"Lechapt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00e9na\u00eblle","family":"Levallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1857_bib0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ijc.24711","article-title":"Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980and 2005","volume":"126","author":"Le Stang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup Environ Med"},{"key":"10.1684\/bdc.2013.1857_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1440-1843.2007.01187.x","article-title":"Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure","volume":"13","author":"Metintas","year":"2008","journal-title":"Respirology"},{"key":"10.1684\/bdc.2013.1857_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwh025","article-title":"Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973through 2003","volume":"159","author":"Price","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1684\/bdc.2013.1857_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/thx.2007.081430","article-title":"Population based epidemiology and prognosis of mesothelioma in Leeds, UK","volume":"63","author":"Chapman","year":"2008","journal-title":"Thorax"},{"key":"10.1684\/bdc.2013.1857_bib0030","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.lungcan.2004.04.010","article-title":"Epidemiology of malignant mesothelioma in Australia","volume":"45","author":"Musk","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0035","doi-asserted-by":"crossref","unstructured":"Ch\u00e9ri\u00e9-Challine L, Imbernon E. D\u00e9claration obligatoire des m\u00e9soth\u00e9liomes: contexte, r\u00e9sultats de la phase pilote, perspectives. BEH Web 2012; 1: http:\/\/www.invs.sante.fr\/behweb\/2012\/01\/index.htm","DOI":"10.1016\/j.respe.2012.06.362"},{"key":"10.1684\/bdc.2013.1857_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2105\/AJPH.86.2.179","article-title":"Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis","volume":"86","author":"Stayner","year":"1996","journal-title":"Am J Public Health"},{"key":"10.1684\/bdc.2013.1857_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1525-1500.1999.99018.x","article-title":"Dose-response relationship between amphibole fiber lung burden and mesothelioma","volume":"23","author":"Rodelsperger","year":"1999","journal-title":"Cancer Detect Prev"},{"key":"10.1684\/bdc.2013.1857_bib0050","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.22552","article-title":"Update on the molecular biology of malignant mesothelioma","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/jcp.52.7.535","article-title":"Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia","volume":"52","author":"Scurry","year":"1999","journal-title":"J Clin Pathol"},{"key":"10.1684\/bdc.2013.1857_bib0060","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1684\/bdc.2013.1857_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","article-title":"Frequent mutations of NF2and allelic loss from chromosome band 22q12in malignant mesothelioma: evidence for a two-hit mechanism of NF2inactivation","volume":"24","author":"Cheng","year":"1999","journal-title":"Genes Chrom Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0070","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization and tumorigenesis\u2013the NF2tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes Dev"},{"key":"10.1684\/bdc.2013.1857_bib0075","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","article-title":"Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK","volume":"25","author":"Poulikakos","year":"2006","journal-title":"Oncogene"},{"issue":"3000","key":"10.1684\/bdc.2013.1857_bib0080","article-title":"Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098in pts with advanced solid tumors","volume":"30","author":"Soria","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0085","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/carcin\/23.7.1127","article-title":"Alterations of the p16(INK4) locus in human malignant mesothelial tumors","volume":"23","author":"Hirao","year":"2002","journal-title":"Carcinogenesis"},{"issue":"Suppl 1","key":"10.1684\/bdc.2013.1857_bib0090","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.lungcan.2005.03.017","article-title":"Implications of P16\/CDKN2A deletion in pleural mesotheliomas","volume":"49","author":"Ladanyi","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0095","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/jnci\/87.24.1870","article-title":"Immunohistochemical analysis of the p16INK4cyclin-dependent kinase inhibitor in malignant mesothelioma","volume":"87","author":"Kratzke","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2013.1857_bib0100","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1038\/sj.onc.1205381","article-title":"Progressive aberrant methylation of the RASSF1A gene in simian virus 40infected human mesothelial cells","volume":"21","author":"Toyooka","year":"2002","journal-title":"Oncogene"},{"key":"10.1684\/bdc.2013.1857_bib0105","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1074\/jbc.R800073200","article-title":"The Rassf family of tumor suppressor polypeptides","volume":"284","author":"Avruch","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1684\/bdc.2013.1857_bib0110","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/1078-0432.CCR-11-2797","article-title":"An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002trial","volume":"18","author":"de Fraipont","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","author":"Hamaratoglu","year":"2006","journal-title":"Nat Cell Biol"},{"key":"10.1684\/bdc.2013.1857_bib0120","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2741\/1953","article-title":"WNT signaling in malignant mesothelioma","volume":"11","author":"Fox","year":"2006","journal-title":"Front Biosci"},{"key":"10.1684\/bdc.2013.1857_bib0125","first-page":"4547","article-title":"Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin","volume":"63","author":"Uematsu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0130","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1158\/0008-5472.CAN-04-1227","article-title":"An anti-Wnt-2monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth","volume":"64","author":"You","year":"2004","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0135","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/0008-5472.CAN-04-1389","article-title":"Wnt inhibitory factor-1is silenced by promoter hypermethylation in human lung cancer","volume":"64","author":"Mazieres","year":"2004","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2013.1857_bib0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/labinvest.2008.168","article-title":"PAX5is expressed in small-cell lung cancer and positively regulates c-Met transcription","volume":"89","author":"Kanteti","year":"2009","journal-title":"Lab Invest"},{"key":"10.1684\/bdc.2013.1857_bib0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e3182417da5","article-title":"Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157cases from the MESOPATH Group","volume":"7","author":"Levallet","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0155","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1is commonly inactivated by somatic mutations and 3p21.1losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1684\/bdc.2013.1857_bib0160","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1684\/bdc.2013.1857_bib0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1684\/bdc.2013.1857_bib0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1684\/bdc.2013.1857_bib0175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma","volume":"3","author":"Creaney","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0180","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0185","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1684\/bdc.2013.1857_bib0190","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0195","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/JTO.0b013e3182730e0e","article-title":"Robust data: the essential foundation of a revised staging system for pleural mesothelioma","volume":"7","author":"Kindler","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"issue":"Suppl 1","key":"10.1684\/bdc.2013.1857_bib0205","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.lungcan.2005.03.007","article-title":"The role of PET in the surgical management of malignant pleural mesothelioma","volume":"49","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0210","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1684\/bdc.2013.1857_bib0215","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0220","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.rmed.2006.10.018","article-title":"Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma","volume":"101","author":"Scherpereel","year":"2007","journal-title":"Respir Med"},{"key":"10.1684\/bdc.2013.1857_bib0225","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy","volume":"108","author":"Boutin","year":"1995","journal-title":"Chest"},{"key":"10.1684\/bdc.2013.1857_bib0230","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1148\/radiol.2412051020","article-title":"Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided versus biopsy surgical biopsy","volume":"241","author":"Agarwal","year":"2006","journal-title":"Radiology"},{"key":"10.1684\/bdc.2013.1857_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjc.6601957","article-title":"A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma","volume":"91","author":"Bydder","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2007.05.022","article-title":"A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma","volume":"84","author":"O'Rourke","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0245","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.7509","article-title":"Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0or less malignant pleural mesothelioma (MPM) (EORTC 08031)","volume":"27","author":"Van Schil","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0250","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","article-title":"Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial","volume":"36","author":"Van Schil","year":"2010","journal-title":"Eur Respir J"},{"issue":"Suppl 4","key":"10.1684\/bdc.2013.1857_bib0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdp134","article-title":"Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Stahel","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0260","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0265","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/JTO.0b013e318272601f","article-title":"Tomotherapy after pleurectomy\/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung","volume":"7","author":"Minatel","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0270","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0275","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0280","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdj073","article-title":"A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial","volume":"17","author":"O'Brien","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0285","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0290","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program","volume":"3","author":"Taylor","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0305","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7030","key":"10.1684\/bdc.2013.1857_bib0310","article-title":"Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial","volume":"30","author":"Hassan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0315","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"10.1684\/bdc.2013.1857_bib0320","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0325","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.7020","article-title":"IFCT-GFPC-0701MAPS trial, a multicenter randomized phase II\/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma","volume":"28","author":"Zalcman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0330","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1684\/bdc.2013.1857_bib0335","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0340","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jcph.148","article-title":"Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors","volume":"53","author":"Xin","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1684\/bdc.2013.1857_bib0345","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01534421","article-title":"Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model","volume":"39","author":"Bielefeldt-Ohmann","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1684\/bdc.2013.1857_bib0350","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00000421-199402000-00018","article-title":"Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma","volume":"17","author":"Ardizzoni","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1684\/bdc.2013.1857_bib0355","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1857_bib0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","article-title":"Regression of AK7malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma","volume":"10","author":"Cordier Kellerman","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1684\/bdc.2013.1857_bib0365","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jtcvs.2003.08.034","article-title":"Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma","volume":"127","author":"Kruklitis","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1684\/bdc.2013.1857_bib0370","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"Monnet","year":"2002","journal-title":"Chest"},{"key":"10.1684\/bdc.2013.1857_bib0375","first-page":"4419","article-title":"Intrapleural production of interleukin 6during mesothelioma and its modulation by gamma-interferon treatment","volume":"54","author":"Monti","year":"1994","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2013.1857_bib0380","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2013.1857_bib0385","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511530165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T23:56:32Z","timestamp":1721606192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511530165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S000745511530165X"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1857","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}